The type of pharmacological drug–drug interaction between CAM and CDDP disclaims potential application of combined treatment in BC cells; however, this interaction could be completely different in other cancer cell lines in which SIRT1 and SIRT2 are involved and in combination with different anti-cancer drugs. The gene discussed is SIRT2; the disease is cancer.